UA99309C2 - Замещенные пиперидинодигидротиенопиримидины - Google Patents

Замещенные пиперидинодигидротиенопиримидины

Info

Publication number
UA99309C2
UA99309C2 UAA201005780A UAA201005780A UA99309C2 UA 99309 C2 UA99309 C2 UA 99309C2 UA A201005780 A UAA201005780 A UA A201005780A UA A201005780 A UAA201005780 A UA A201005780A UA 99309 C2 UA99309 C2 UA 99309C2
Authority
UA
Ukraine
Prior art keywords
diseases
dihydrothienopyrimidines
piperidinodihydrothienopyrimidines
novel
relates
Prior art date
Application number
UAA201005780A
Other languages
English (en)
Ukrainian (uk)
Inventor
Паскаль Пузе
Ральф Андерскевітц
Хорст Доллінгер
Денніс Фіген
Томас Фокс
Рольф Гьоггель
Крістоф Хьонке
Домнік Мартірес
Петер Ніколаус
Клаус Кліндер
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99309(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA99309C2 publication Critical patent/UA99309C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны новые пиперидинодигидротиенопиримидины формулы (1) (1), в которой X означает SO или SO2, преимущественно SO, a R1, R2, R3 и R4 могут иметь указанные в п. 1 формулы изобретения значения, а также их фармакологически приемлемые соли и фармацевтические композиции, которые содержат такие соединения. Эти новые пиперидинодигидротиенопиримидины пригодны для лечения недомоганий, обусловленных нарушением функции дыхательных путей или желудочно-кишечного тракта, заболеваний дыхательных путей или желудочно-кишечного тракта, воспалительных заболеваний суставов, кожи или глаз, заболеваний периферической или центральной нервной системы или онкологических заболеваний.
UAA201005780A 2007-10-19 2008-10-16 Замещенные пиперидинодигидротиенопиримидины UA99309C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118901 2007-10-19

Publications (1)

Publication Number Publication Date
UA99309C2 true UA99309C2 (ru) 2012-08-10

Family

ID=39154006

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201005780A UA99309C2 (ru) 2007-10-19 2008-10-16 Замещенные пиперидинодигидротиенопиримидины

Country Status (33)

Country Link
US (1) US8754073B2 (ru)
EP (3) EP2610258B1 (ru)
JP (2) JP5150728B2 (ru)
KR (1) KR101548975B1 (ru)
CN (2) CN101827852B (ru)
AR (1) AR069075A1 (ru)
AT (1) ATE542825T1 (ru)
AU (1) AU2008313660B2 (ru)
BR (1) BRPI0818006B8 (ru)
CA (1) CA2705414C (ru)
CL (1) CL2008003096A1 (ru)
CY (2) CY1112703T1 (ru)
DK (2) DK2610258T3 (ru)
EA (1) EA019480B1 (ru)
EC (1) ECSP10010156A (ru)
ES (2) ES2381452T3 (ru)
HR (2) HRP20120334T1 (ru)
MA (1) MA31845B1 (ru)
ME (1) ME01330B (ru)
MX (1) MX2010004026A (ru)
MY (1) MY153979A (ru)
NZ (1) NZ585346A (ru)
PE (2) PE20131463A1 (ru)
PL (2) PL2610258T3 (ru)
PT (2) PT2610258E (ru)
RS (1) RS52271B (ru)
SI (2) SI2215092T1 (ru)
TN (1) TN2010000175A1 (ru)
TW (1) TWI421077B (ru)
UA (1) UA99309C2 (ru)
UY (1) UY31405A1 (ru)
WO (1) WO2009050248A1 (ru)
ZA (1) ZA201001683B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
PL2205608T3 (pl) * 2007-10-18 2013-09-30 Boehringer Ingelheim Int Sposób otrzymywania dihydrotieno[3,2-d]pirymidyn i związków pośrednich stosowanych w tym sposobie
BRPI0817781A2 (pt) * 2007-10-19 2019-09-24 Boehringer Ingelheim Int piperazino-diidroteinopirimidinas substituídas com heterociclo
MY153979A (en) * 2007-10-19 2015-04-30 Boehringer Ingelheim Int Substituted piperidino-dihydrothienopyrimidine
JP5563466B2 (ja) 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
WO2011124525A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2555773A1 (de) 2010-04-08 2013-02-13 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
MX2015009677A (es) * 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida novedosos.
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN104892720B (zh) * 2014-03-07 2016-10-26 华东师范大学 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
CA3029305C (en) * 2016-06-30 2024-02-13 Riken 2-(piperidin-1-yl)-pyrimidin-4(3h)-ones useful as tankyrase inhibitors
WO2019057806A1 (en) 2017-09-20 2019-03-28 Leo Pharma A/S SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
PT3700529T (pt) 2017-10-23 2025-09-17 Boehringer Ingelheim Int Nova combinação de agentes ativos para o tratamento das doenças pulmonares intersticiais fibrosantes progressivas (dpi-fp
US11384096B2 (en) 2017-12-15 2022-07-12 UNION therapeutics A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
CN111712502B (zh) 2017-12-15 2023-10-27 联合疗法公司 取代的氮杂环丁烷二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
CN111712503B (zh) * 2017-12-15 2024-04-09 联合疗法公司 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
WO2020048827A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
EP4426307B1 (en) 2021-12-09 2025-07-02 Boehringer Ingelheim International GmbH New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
TW202342050A (zh) 2021-12-09 2023-11-01 德商百靈佳殷格翰國際股份有限公司 用於治療進行性纖維化間質性肺病之新穎治療組合
TW202402289A (zh) * 2022-06-02 2024-01-16 大陸商西藏海思科製藥有限公司 Pde4b抑制劑及其用途
CN117247395A (zh) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 Pde4b抑制剂
CN115040503B (zh) * 2022-07-26 2023-10-10 云南民族大学 螺环二烯酮型木脂素类化合物在制药中的应用
IL318673A (en) * 2022-08-09 2025-03-01 Xizang Haisco Pharmaceutical Co Ltd PDE4B inhibitor and its use
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
WO2024067660A1 (zh) * 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
KR20250174586A (ko) * 2023-02-28 2025-12-12 이노웨이스톤 테라퓨틱스 리미티드 디하이드로티에노피리미딘 유도체의 제조 방법 및 용도
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
WO2024213089A1 (zh) * 2023-04-13 2024-10-17 上海壹迪生物技术有限公司 取代的二氢噻吩并嘧啶类化合物、其制备方法和应用
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
WO2025038987A2 (en) * 2023-08-17 2025-02-20 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
WO2025161532A1 (zh) * 2024-02-01 2025-08-07 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (ru) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (ru) 1965-03-31
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (ru) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
WO2001052902A1 (en) 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
CA2425539C (en) 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
EP1401840A4 (en) 2001-04-30 2007-05-16 Bayer Corp NEW 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3 D | PYRIMIDINE
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
HUP0400333A3 (en) 2001-06-22 2012-10-29 Boehringer Ingelheim Pharma Crystalline anticholinergic, method for its production, and use thereof in the production of pharmaceutical composition
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
ES2305435T3 (es) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
CA2526985A1 (en) 2003-05-16 2004-12-02 Wisconsin Alumni Research Foundation Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
CA2801065C (en) 2003-10-02 2020-04-28 Dsm Ip Assets B.V. Production of high levels of dha in microalgae using modified amounts of chloride and potassium
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DK1701951T3 (da) 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
WO2006120176A2 (en) 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP2137196B1 (en) 2007-04-20 2010-10-06 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
PL2205608T3 (pl) 2007-10-18 2013-09-30 Boehringer Ingelheim Int Sposób otrzymywania dihydrotieno[3,2-d]pirymidyn i związków pośrednich stosowanych w tym sposobie
JP5563466B2 (ja) 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
JP2011500621A (ja) 2007-10-19 2011-01-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
CL2008003085A1 (es) 2007-10-19 2009-10-09 Astrazeneca Ab Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
BRPI0817781A2 (pt) 2007-10-19 2019-09-24 Boehringer Ingelheim Int piperazino-diidroteinopirimidinas substituídas com heterociclo
MY153979A (en) * 2007-10-19 2015-04-30 Boehringer Ingelheim Int Substituted piperidino-dihydrothienopyrimidine
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
WO2010097334A1 (de) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CA2753597A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
MY153979A (en) 2015-04-30
CN101827852B (zh) 2014-07-30
JP5615889B2 (ja) 2014-10-29
PL2610258T3 (pl) 2015-02-27
KR101548975B1 (ko) 2015-09-01
JP5150728B2 (ja) 2013-02-27
BRPI0818006A2 (pt) 2015-12-22
CY1112703T1 (el) 2016-02-10
ME01330B (me) 2013-12-20
US8754073B2 (en) 2014-06-17
HK1145677A1 (en) 2011-04-29
CA2705414C (en) 2016-05-24
SI2610258T1 (sl) 2014-12-31
CN101827852A (zh) 2010-09-08
CA2705414A1 (en) 2009-04-23
ECSP10010156A (es) 2010-06-29
MA31845B1 (fr) 2010-11-01
ES2381452T3 (es) 2012-05-28
EA019480B1 (ru) 2014-04-30
WO2009050248A1 (de) 2009-04-23
TN2010000175A1 (fr) 2011-11-11
AU2008313660B2 (en) 2013-11-07
MX2010004026A (es) 2010-04-30
RS52271B (sr) 2012-10-31
KR20100100807A (ko) 2010-09-15
SI2215092T1 (sl) 2012-04-30
HRP20141153T1 (hr) 2015-02-13
ZA201001683B (en) 2010-10-27
PE20131463A1 (es) 2013-12-23
UY31405A1 (es) 2009-05-29
JP2011500640A (ja) 2011-01-06
EP2610258A1 (de) 2013-07-03
PL2215092T3 (pl) 2012-07-31
EP2215092A1 (de) 2010-08-11
HRP20120334T1 (hr) 2012-05-31
ES2524910T3 (es) 2014-12-15
AR069075A1 (es) 2009-12-30
CL2008003096A1 (es) 2010-02-12
EP2380891A1 (de) 2011-10-26
CY1115858T1 (el) 2017-01-25
PT2610258E (pt) 2014-10-24
PT2215092E (pt) 2012-04-10
DK2610258T3 (da) 2014-11-10
NZ585346A (en) 2011-09-30
DK2215092T3 (da) 2012-05-07
EP2215092B1 (de) 2012-01-25
EA201000609A1 (ru) 2010-10-29
BRPI0818006B8 (pt) 2021-05-25
TWI421077B (zh) 2014-01-01
EP2610258B1 (de) 2014-08-27
US20110021501A1 (en) 2011-01-27
CN104069112A (zh) 2014-10-01
TW200918074A (en) 2009-05-01
JP2013064001A (ja) 2013-04-11
AU2008313660A1 (en) 2009-04-23
EP2380891B1 (de) 2013-12-11
BRPI0818006B1 (pt) 2019-10-22
PE20091386A1 (es) 2009-10-17
ATE542825T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MX2008012915A (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias.
EA200901373A1 (ru) Аминогетероциклические соединения
PH12012501222A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
MY177111A (en) Substituted amide derivatives and methods of use
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
WO2007135026A3 (de) Substituierte pteridine als therapeutika
MX2009014001A (es) Derivados de isoxazol-imidazol.
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES